Skip to content
Search
Close
  • Home
  • About Us
    • Company Overview
    • Leadership Team
    • Board of Directors
    • Investors
  • Our Solution
    • CSF-1 Overview
    • About Presbyopia
    • Mechanism of Action
  • News & Events
  • CONTACT
Menu
  • Home
  • About Us
    • Company Overview
    • Leadership Team
    • Board of Directors
    • Investors
  • Our Solution
    • CSF-1 Overview
    • About Presbyopia
    • Mechanism of Action
  • News & Events
  • CONTACT
  • Home
  • About Us
    • Company Overview
    • Leadership Team
    • Board of Directors
    • Investors
  • Our Solution
    • CSF-1 Overview
    • About Presbyopia
    • Mechanism of Action
  • News & Events
  • Contact Us
  • Orasis Announces the Appointment of Jeffry Weinhuff as Chairman of the Board of Directors

    • Post author:foothold
    • Post published:October 22, 2018
    • Post category:Press Releases

    HERZLIYA, Israel, October 22, 2018 – Orasis Pharmaceuticals LTD. a clinical-stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an alternative to reading glasses, today…

    Continue ReadingOrasis Announces the Appointment of Jeffry Weinhuff as Chairman of the Board of Directors

    Recent Posts

    • FDA Accepts Orasis Pharmaceuticals’ New Drug Application for CSF-1 for the Treatment of Presbyopia 
    • Orasis Pharmaceuticals Submits New Drug Application for Investigational Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia
    • Orasis Pharmaceuticals Announces Phase 2b Trial Efficacy and Safety Results of Novel Presbyopia Eye Drop Candidate, CSF-1, at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
    • Orasis Pharmaceuticals Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia
    • Orasis Pharmaceuticals to Present New Data on Novel Presbyopia Candidate at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

    Recent Comments

      Archives

      • February 2023
      • January 2023
      • April 2022
      • March 2022
      • October 2021
      • April 2021
      • October 2020
      • September 2020
      • October 2019
      • March 2019
      • December 2018
      • November 2018
      • October 2018
      • June 2018

      Categories

      • Press Releases
      • Events

      Meta

      • Log in
      • Entries feed
      • Comments feed
      • WordPress.org

      HOME

      ABOUT US

      • Company Overview
      • Leadership Team
      • Board of Directors
      • Investors
      • Company Overview
      • Leadership Team
      • Board of Directors
      • Investors

      OUR SOLUTION

      • CSF-1 Overview
      • About Presbyopia
      • Mechanism of Action
      • CSF-1 Overview
      • About Presbyopia
      • Mechanism of Action

      NEWS & EVENTS

      CONTACT

      info@orasis-pharma.com
      Linkedin-in Twitter